Navigation Links
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
Date:2/14/2008

- New Data Presented at American Society of Clinical Oncology's

Genitourinary Symposium -

SEATTLE and SAN FRANCISCO, Feb. 14 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (Nasdaq: DNDN) today presented data demonstrating the correlation of a measure of the cumulative potency of PROVENGE (sipuleucel-T), an investigational active cellular immunotherapy for hormone-refractory prostate cancer, with overall survival. This is the first time that an association between higher potency of an active immune therapy and increased patient survival has been reported. The correlation appeared to be independent of other important baseline prognostic factors.

The abstract (#21), "Cell Number and CD54 Expression in Sipuleucel-T Correlate with Survival in Metastatic Androgen Independent Prostate Cancer," is being presented at the American Society of Clinical Oncology's 2008 Genitourinary Symposium in San Francisco.

In two Phase 3 trials, D9901 and D9902A, researchers evaluated cumulative product release parameters of PROVENGE, including CD54 upregulation (a measure of product potency defined as the increase of CD54 molecules expressed on Antigen Presenting Cells [APC] after incubation with the PROVENGE Antigen Delivery Cassette(TM)) and the number of total nucleated cells (TNCs) among patients treated with sipuleucel-T (n=146). CD54 is a costimulatory molecule which serves as a marker for APCs. Its expression is increased when APCs become activated and this upregulation of CD54 serves as a potency release assay for PROVENGE.

Results showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... ST. LOUIS, Nov. 6 Reces...ed to depress sales for Allied Healthcare Products...eptember 30, 2009. ,, Sales declines pushed All... the quarter was about $745,000, or negative 9 cen...rlier of about $208,000, or 3 cents per share. ,...
(Date:11/6/2009)... SAN DIEGO, Nov. 6 Trius Therapeut...stration statement on Form S-1 with the U.S. Secur...proposed initial public offering of shares of its ... sold in the offering will be offered by the Compa...ting as sole book-running manager, Piper Jaffray &...
(Date:11/6/2009)... WESTBURY, N.Y., Nov. 6 Repossessi...hine tools in the third quarter of 2009 declined a... to Nassau Asset Management,s NasTrac Quarterly In... activity reports for both repossessions and order...sions for both construction and printing equipment...
Breaking Medicine Technology:Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Immigration Attorneys Make Immigration Law 26amp 3B Employment Visas Easier for Foreign Workers U S Employers Corporations and Corporate Counsel 53725 1Immigration Attorneys Make Immigration Law 26amp 3B Employment Visas Easier for Foreign Workers U S Employers Corporations and Corporate Counsel 53725 2Immigration Attorneys Make Immigration Law 26amp 3B Employment Visas Easier for Foreign Workers U S Employers Corporations and Corporate Counsel 53725 3Immigration Attorneys Make Immigration Law 26amp 3B Employment Visas Easier for Foreign Workers U S Employers Corporations and Corporate Counsel 53725 4Immigration Attorneys Make Immigration Law 26amp 3B Employment Visas Easier for Foreign Workers U S Employers Corporations and Corporate Counsel 53725 5Medizone Expects OTCBB Listing 53721 1Medizone Expects OTCBB Listing 53721 2ICBS to focus on pharmaceutical and environmental markets 53717 1ICBS to focus on pharmaceutical and environmental markets 53717 2
...R Met Primary Endpoints; Demonstrated Strong Reduc...MINSTER, N.J., May 5, QRxPharma Limited (ASX: QR...any focused on the development,and commercialisati...m,(CNS) disorders, announced today initial Phase 3...e dual-opioid product intended for the acute,manag...
...R, Colo., May 5 N30 Pharma (N30), a,biopharmaceut..., and,commercialization of drugs that target endog...successfully completed Phase I study of N30-201,in... healthy volunteers.,N30 intends to develop N30-20...rway diseases, including Cystic Fibrosis and asthm...
Other Medicine Technology:QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 2QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 3N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201 2
(Date:11/8/2009)... Men’s Health Network (MHN) urges militar...cially those linked to exposure to chemicals, atom... Bladder cancer is one of those cancers that is tw...se who once smoked or currently smoke cigarettes. ...ovember 8, 2009 -- Men’s Health Network (MHN...
(Date:11/8/2009)... 7 USAction this evenin... America Act, which will make health care more aff...countable and increase access to health care for m..., "Teddy Roosevelt, FDR and Harry Truman would be ...y. "Today,s vote ranks among our country,s proudes...
(Date:11/8/2009)...e Shows Who Sides With Working Families vs. Insura...wswire-USNewswire/ -- On the heels of an historic ...r a good, balanced health care reform bill, the Pe... state,s U.S. representatives voted on HR 3962, th...he legislation, which passed Saturday evening by a...
(Date:11/7/2009)... The American Medical A...ush Award for Citizenship and Community Service to...cago, IL. The award recognizes physicians who have...duty to make an outstanding public service contrib... the award today during the opening session of the...
(Date:11/7/2009)... 7 With the final House...remists are holding the entire bill hostage to fur... that the bill go far beyond the status quo restri... the original bill. In an outrageous amendment, w...ernoon, antichoice Democrats are demanding explici...
Breaking Medicine News(10 mins):Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 2Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 3Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2
...ional seed with a bright-blooming relative offers ...d reducing harmful cholesterol.// Corn oil and ... as an ingredient could appear on supermarket shel... popcorn and yellow sweet corn. Scientists bre...
...ly to use indoor tanning booths than boys and to u...ve University study.// The study found nearly...door tanning facility at least once, and nearly 30...s 11.2 per cent of 13- to 14-year-olds and 47 perc...
...jars of pasta sauces because they contain a cancer...lish.// Sky News said consumers are being war...li, as well as private-label sauces made for super... -- classified as a carcinogen by the Internationa...
... has alarmed researchers who say a decline in milk...he Mayo Clinic in Rochester, Minnesota, examined d...tion recorded between 1999 and 2001. They found th...inologist at the clinic and the lead author of the...
...cence may mean teenagers smokers are more likely t...he habit as adults, suggests a new rat study.// ...r someone starts smoking, the more likely they are...l Center in Durham, North Carolina, US. Exp...
...e than skin-deep. Researchers from the University ... made of tea, they say could fight skin cancer.// ...ay appear to block skin tumors. Polyphenols are fo... enzyme JNK-2, which naturally increases after ski...
Other Medicine News:Health News:New heart-healthy corn due in stores by 2007 2Health News:,Girls Hit Tanning Booths More Than Boys 2Health News:Teens break bones 'due to lack of milk' 2
Gc-globulin (actin-free) ELISA Kit
...Mark The X & Y Coordinates At The 6 & 9 Oclock Pos...ameter & 13mm Outer Diameter Radial Axis Marks Cov...iated With Hand-Held Markers By Mounting The Devic...ng To Ensure A More Perfect Mark. , ,Etched C...
180.XENON
... diagnostic tool in determining functionality of a...hen deciding courses of treatment for patients rec...tment, recurring infections and autoimmune dieseas... autoimmune diseases giving rise to high titers of...
Medicine Products: